Shire has agreed to license exclusive worldwide rights to two rare cholestatic liver disease candidates, including the maralixibat oral inhibitor, to clinical-stage therapeutics company Mirum Pharmaceuticals.
Alexion Pharmaceuticals has wrapped up its previously announced acquisition of US-based clinical-stage biotechnology firm Syntimmune in a deal worth $1.2bn.
Gilead Sciences and Tango Therapeutics have entered into a global collaboration to discover, develop and commercialize a pipeline of targeted immuno-oncology treatments for cancer.
Terns Pharmaceuticals, a biopharma company focused on discovering and developing molecularly targeted, oral, small-molecule drugs for the treatment of NASH and cancer, has raised $80m through a Series B financing round.
Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.
Alexion Pharmaceuticals and Dicerna Pharmaceuticals have entered into a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases.
Stoke Therapeutics, a US-based biotechnology company focused on the development of drugs for severe genetic diseases, has raised $90m in a Series B financing round.
Private equity firm Bain Capital has joined forces with US pharma giant Pfizer to create a new biopharmaceutical company, dubbed Cerevel Therapeutics, which will focus on developing drugs for the treatment of central nervous system (CNS) disorders.
China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.
FSD Pharma has signed a binding letter of intent (LOI) to acquire Therapix Biosciences, a NASDAQ traded pharmaceutical company focused on the development of Cannabinoid-based treatments.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.